Next Article in Journal
Dissolution Profile of Mefenamic Acid Solid Dosage Forms in Two Compendial and Biorelevant (FaSSIF) Media
Previous Article in Journal
Cholesterol-Lowering Effect of Beta Glucan Extracted from Saccharomyces cerevisiae in Rats
 
 
Scientia Pharmaceutica is published by MDPI from Volume 84 Issue 3 (2016). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Austrian Pharmaceutical Society (Österreichische Pharmazeutische Gesellschaft, ÖPhG).
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Prevalence of Adverse Drug Reactions in CAD STEMI Patients Treated in the Cardiac Intensive Care Unit at the Public Hospital in Bandung, Indonesia

by
Lia AMALIA
1,*,
Kusnandar ANGGADIREJA
1,
Toni M. APRAMI
2 and
Vina SEPTIANI
1
1
School of Pharmacy, Institut Teknologi Bandung, Indonesia.
2
Faculty of Medicine, Universitas Padjajaran, Indonesia.
*
Author to whom correspondence should be addressed.
Sci. Pharm. 2016, 84(1), 167-179; https://doi.org/10.3797/scipharm.ISP.2015.08
Submission received: 5 September 2015 / Accepted: 15 December 2015 / Published: 14 February 2016

Abstract

Adverse drug reactions (ADRs) are associated with morbidity, mortality, and can contribute to increased healthcare costs.This study was conducted to identify the occurence, types, and management of ADRs, as well as analyze the causal relationship, severity, and preventability of ADRs. The study was observational analysis with concurrent data collection from patients with Coronary Artery Disease-ST segment Elevation Myocardial Infarction (CAD-STEMI) treated in the Cardiac Intensive Care Unit (CICU) at a hospital in Bandung Indonesia, during the period of December 2013 to March 2014. The occurence of identified ADRs was assessed using the probability scale of Naranjo, while the severity by the scale of Hartwig and their preventability was evaluated using the scale of Schumock-Thornton. 49 ADRs were identified in 29 patients. Organ systems most affected by the ADRs were the cardiovascular and body electrolyte, each accounting for 20.41%. The hematology and gastrointestinal systems each contributed 18.37% to ADR occurrences. The causal relationship was mostly classified as “probable,” accounting for 69.39%. With regard to severity, most ADRs were classified as “moderate” at level 3, contributing to 53.06% of the occurence. In terms of preventability, most of the ADRs fell into the “non-preventable” category (79.59%). The most widely applied ADRs management was administration of an antidote or other treatments (40.82%). Further analysis revealed that the average number of drug types and duration of hospitalization significantly affected the presence of ADRs. Taken together, most patients with CAD STEMI treated in the CICU of the studied hospital experienced non-preventable ADRs and were treated with antidote or other treatments.
Keywords: ADRs; CAD STEMI; Naranjo; Hartwig; Schumock-Thornton scales ADRs; CAD STEMI; Naranjo; Hartwig; Schumock-Thornton scales

Share and Cite

MDPI and ACS Style

AMALIA, L.; ANGGADIREJA, K.; APRAMI, T.M.; SEPTIANI, V. Prevalence of Adverse Drug Reactions in CAD STEMI Patients Treated in the Cardiac Intensive Care Unit at the Public Hospital in Bandung, Indonesia. Sci. Pharm. 2016, 84, 167-179. https://doi.org/10.3797/scipharm.ISP.2015.08

AMA Style

AMALIA L, ANGGADIREJA K, APRAMI TM, SEPTIANI V. Prevalence of Adverse Drug Reactions in CAD STEMI Patients Treated in the Cardiac Intensive Care Unit at the Public Hospital in Bandung, Indonesia. Scientia Pharmaceutica. 2016; 84(1):167-179. https://doi.org/10.3797/scipharm.ISP.2015.08

Chicago/Turabian Style

AMALIA, Lia, Kusnandar ANGGADIREJA, Toni M. APRAMI, and Vina SEPTIANI. 2016. "Prevalence of Adverse Drug Reactions in CAD STEMI Patients Treated in the Cardiac Intensive Care Unit at the Public Hospital in Bandung, Indonesia" Scientia Pharmaceutica 84, no. 1: 167-179. https://doi.org/10.3797/scipharm.ISP.2015.08

Article Metrics

Back to TopTop